PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Study reveals AI can predict patients’ survival in glioblastoma

The aggressive brain cancer is responsible for over 3,000 cases in the UK every year.

Researchers from King’s College London (KCL) have developed an artificial intelligence (AI)-based model that can predict adult brain cancer patients’ rates of survival after receiving radiotherapy treatment.

Published in Neuro-Oncology, researchers applied deep learning to predict whether glioblastoma patients would survive eight months.

Responsible for around 3,200 cases every year in the UK, glioblastoma is a very aggressive and difficult-to-treat cancer, with just one in four patients surviving over one year after diagnosis.

Currently, patients are regularly and routinely tested to see whether chemotherapy is effective or not. However, some patients can suffer from harmful side effects as a result of chemotherapy.

Instead, by giving patients an instantaneous and accurate prediction from a single routine MRI scan, the AI will allow doctors to identify patients who would not benefit from chemotherapy and try a different course of treatment or begin an experimental treatment in a clinical trial.

After training the AI on a dataset of over 10,000 scans from a variety of patients with brain cancer, it “showed improved performances when first trained to detect abnormalities,” explained Alysha Chelliah, PhD researcher, KCL.

Dr Thomas Booth, reader in neuroimaging, school of biomedical engineering and imaging sciences, KCL, added: “The AI was able to give us an immediate and accurate prediction, which means clinicians can empower patients to make choices about their treatment.”

Involving a collaboration of 11 neuro-oncology centres across the UK, the use of AI to predict short-term and long-term survivors within eight months of radiotherapy would allow clinicians to be better informed for treatment planning and refer patients to potentially life-saving treatments quicker.

Dr Michele Afif, chief executive officer, The Brain Tumour Charity, said that the study findings “to evaluate and predict response to radiotherapy at a much earlier point… is a hugely important step in tackling this notoriously difficult-to-treat disease”.

Researchers hope to see the cancer research community using this tool “to see improved outcomes for patients who won’t benefit from the usual course of chemotherapy,” added Booth.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026